Cerenome Earnings Call Transcripts
Fiscal Year 2026
-
CNSide achieved 158 million covered lives and began billing, with Medicare rates expected in early 2027. Test volumes and menu expansion are on track, and gross billings reached $1.55 million on 222 tests. Annualized run rate is projected at $10–12.5 million, with cash runway into 2028.
-
Rebranding to Cerenome reflects a broader CNS oncology focus, integrating therapeutics, diagnostics, and AI-driven data. REYOBIQ and CNSide platforms are advancing on all 2026 objectives, with payer coverage, clinical trial progress, and AI initiatives on track to drive operational efficiency and growth.
-
The meeting covered board elections, auditor ratification, executive compensation, and a stock plan amendment, all of which were approved. Voting procedures were clarified, and a reverse stock split was noted as recently effective.
-
A $15M capital raise extends funding through 2027, supporting clinical and commercial milestones. CNSIDE aims for break-even by 2027, with profitability requiring ~5,000 tests/year. Key 2026 goals include pivotal trial readiness, expanded payer coverage, and increased test utilization.
Fiscal Year 2025
-
CNside is positioned to transform CNS cancer diagnostics with a highly sensitive, patented platform and a $6 billion U.S. market opportunity. Commercial launch begins in Texas in Q3 2025, with national expansion and payer agreements underway. Financial guidance will be updated in Q1 2026.
Fiscal Year 2024
-
Closed $15M equity financing and received $2M in grant funding, extending runway through mid-2026. Advanced Rheobic clinical programs with strong efficacy signals in LM and GBM, and set for CNSide commercial launch in 2025. CNSide targets a sizable diagnostic market opportunity.
-
Clinical programs for RNL in LM and GBM advanced with strong safety and efficacy data, while CNSide diagnostic platform is set for commercial launch in early 2025. Financial position is supported by grants, private placement, and expanded manufacturing, with key regulatory and clinical milestones expected through 2025.
-
The conference featured advances in targeted radiotherapeutics for CNS tumors, with clinical programs showing strong safety and efficacy signals. Key milestones include upcoming data readouts, a new diagnostic launch by Q4 2024, and funding secured into 2026.
-
Clinical trials for LM and GBM showed encouraging safety and efficacy signals, with CNSide diagnostics influencing over 90% of treatment decisions and demonstrating superior sensitivity. Cash position remains stable, bolstered by grants and a recent private placement, with multiple data updates and regulatory milestones expected in late 2024.